English
Regional settings| Spread | 0.27 | ||||
 Long position overnight feeLong position overnight fee
Trade size with leverage ~ $5,000.00 Short position overnight fee ~ $4,000.00 | -0.026179% | ||||
| Short position overnight fee Short position overnight fee
Trade size with leverage ~ $5,000.00 Short position overnight fee ~ $4,000.00 | 0.003957% | ||||
| Overnight fee time | 21:00 (UTC) | ||||
| Currency | USD | ||||
| Min traded quantity | 1 | ||||
| Margin | 20 | ||||
| Stock exchange | United States of America | ||||
| Commission on trade1 | 0% |
1Our charge for executing your trade is the spread, the difference between the buy and sell price. Please consult the Charges and Fees section of our website for further information
| Prev. Close | 97.33 |
| Open | 94.94 |
| 1-Year Change | -49.67% |
| Day's Range | 94.94 - 98.01 |
ICU Medical, Inc. (ICU) is engaged in the development, manufacturing and sale of medical products used in infusion therapy and critical care applications. The Company’s product portfolio includes IV solutions, IV smart pumps with pain management and safety software technology, dedicated and non-dedicated IV sets and needlefree connectors designed to help meet clinical, safety and workflow goals. Its critical care products help clinicians get real-time access to patients’ hemodynamic and cardiac status with a portfolio of monitoring systems and advanced sensors and catheters. Its primary critical care products include Cogent, CardioFlo, TDQ and OptiQ, TriOx, Transpac and SafeSet. It sells its products through its direct sales force and through independent distributors. Its IV Solutions products include IV Therapy and Diluents, and Irrigation. Its Infusion System products include Infusion Pump Hardware, IV Mediation Safety Software and Professional Services.
BRIEF: For the fiscal year ended 31 December 2021, ICU Medical Inc revenues increased 4% to $1.32B. Net income increased 19% to $103.1M. Revenues reflect Infusion Consumables segment increase of 17% to $555.2M, Critical Care segment increase of 1% to $49.3M, United States segment increase of 3% to $941.8M, EMEA segment increase of 11% to $147.5M. Net income benefited from Restructuring Charges/Provisions decrease of 37% to $18M (expense).
Common Stock $.10 Par, 03/11, 80M auth., 14,855,000 issd., less 1,123,000 shs. in Treas @ $38.95M. Insiders & Strategic holders own 11.33%. IPO 3/92, 1.3M shares @ $11.00 by Sutro& Co., Inc. PO 7/95, 2.07M shares @ $12 by Rodman & Renshaw, Inc. 3/02, 4/93, 3-for-2 stock splits. FY'03 Q4 are being restated.
